Endobronchial Ultrasound Biopsy Market Revenue to Reach USD 1.48 Billion by 2036, China at 8.5% CAGR, India at 7.9%, Germany at 7.2%
The global endobronchial
ultrasound biopsy market is estimated at USD 0.80 billion in 2026 and is
projected to reach USD 1.48 billion by 2036, expanding at a 6.3% CAGR during
the forecast period. The market is gaining from wider use of minimally invasive
mediastinal staging, expanding lung cancer screening programs, and increasing
adoption of image-guided tissue sampling in hospitals and specialty pulmonary
centers.
Endobronchial ultrasound biopsy combines bronchoscopy with
real-time ultrasound imaging to guide tissue sampling from mediastinal lymph
nodes and pulmonary lesions. Fact.MR estimates that the market will add
approximately USD 0.73 billion between 2026 and 2036. Early growth is supported
by increased CP-EBUS adoption in academic hospitals, while broader deployment
in community hospitals and specialty pulmonary clinics is expected to support
demand through the middle of the forecast period.
Get detailed market
forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=14422
EBUS scopes remain a core equipment category
EBUS scopes are projected to account for approximately 36%
of the global market. Their position reflects their role as the central capital
equipment used to combine bronchoscopy with real-time ultrasound imaging during
guided tissue sampling. As hospitals expand minimally invasive diagnostic
capabilities, demand for systems offering imaging clarity and compatibility
with dedicated biopsy needles remains relevant to pulmonary and thoracic
oncology workflows.
Convex-probe linear EBUS systems are expected to hold nearly
45% of the procedure outlook. These systems enable transbronchial needle
aspiration under direct ultrasound guidance, making them particularly relevant
for mediastinal lymph node staging and diagnosis. Their adoption also reflects
the clinical preference for procedures that can reduce dependence on surgical biopsy
approaches in appropriate diagnostic pathways.
The market is also moving toward greater integration between
imaging, navigation, and tissue-sampling technologies. Advanced imaging
processors, disposable EBUS-TBNA needles, and integration with robotic
bronchoscopy systems are expected to influence value creation as healthcare
providers seek more precise and efficient diagnostic workflows.
Shambhu Nath Jha, Principal Consultant at Fact.MR, notes
that the report can help CXOs understand how lung cancer staging protocols,
reimbursement dynamics, and integration with advanced imaging platforms are
shaping demand for EBUS capital equipment and consumables.
China and India lead country-level growth
China is projected to record the highest CAGR among the
countries covered, expanding at 8.5% through 2036. Growth is supported by
expanding tertiary-care infrastructure, increasing oncology diagnostics, and
greater installation of advanced bronchoscopy equipment. India follows with a
7.9% CAGR, driven by rising lung cancer incidence, expanding tertiary
hospitals, and wider access to advanced pulmonary diagnostic services.
Germany is expected to grow at 7.2% CAGR, supported by
structured cancer diagnostic pathways and established pulmonology services.
France is projected to expand at 6.6%, while the United Kingdom is forecast to
record a 6.0% CAGR as hospitals continue to optimize lung cancer referral and
diagnostic pathways.
In North America, the United States is projected to grow at
5.4% CAGR through 2036. Demand remains linked to established tertiary oncology
centers, advanced hospital infrastructure, lung cancer screening, and the
continued use of minimally invasive pulmonary diagnostics. Brazil is expected
to record a 4.7% CAGR as oncology diagnostic capacity gradually expands across
urban healthcare centers.
Asia Pacific remains the fastest-growing regional market,
with China and India serving as major contributors. Growing oncology
infrastructure, physician training, hospital investments, and wider access to
advanced bronchoscopic equipment are shaping procurement decisions across the
region.
Competitive landscape
The competitive environment includes established medical
technology companies with portfolios spanning endoscopic visualization,
ultrasound imaging, biopsy instruments, and integrated diagnostic platforms.
Key companies profiled by Fact.MR include Olympus Corporation, GE HealthCare,
Siemens Healthineers AG, Koninklijke Philips N.V., Boston Scientific
Corporation, Cook Group Incorporated, FUJIFILM Holdings Corporation, and
Medi-Globe Technologies GmbH.
Competition is increasingly influenced by imaging
resolution, biopsy precision, procedural reliability, regulatory compliance,
and compatibility with broader pulmonary and oncology workflows. Manufacturers
are also positioned around integration with robotic bronchoscopy, advanced
imaging, and disposable consumables, allowing healthcare providers to build
more connected diagnostic pathways.
Market Snapshot
The endobronchial ultrasound biopsy market is valued at USD
0.80 billion in 2026 and is forecast to reach USD 1.48 billion by 2036 at a
6.3% CAGR. EBUS scopes account for approximately 36% of the market, while
convex-probe linear EBUS systems represent nearly 45% of the procedure outlook.
Asia Pacific is identified as the fastest-growing region, led by China and
India.
To View Top Reports
https://social.art-inpa.com/blogs/31973/Car-Rental-Market-Forecast-to-USD-263-41-Billion-by
https://sportgalax.com/read-blog/24379
https://afgbfh.blogspot.com/2026/10/car-rental-market-outlook-through-2036.html
About Fact.MR
Fact.MR is a market research and consulting company
providing market intelligence, competitive analysis, and forecasting across
global industries. Its research covers emerging technologies, evolving consumer
trends, industrial developments, and changing business environments. Fact.MR
delivers data-driven insights designed to support strategic planning,
investment decisions, and market-entry initiatives.